Panel Discussion: Redesigning Clinical Trials for Immune Tolerance Therapies: Enhancing Safety, Efficacy, and Regulatory Compliance
Time: 12:00 pm
day: Conference Day One
Details:
• Uncovering the limitations of autoimmune disease models in the context of the maturity of the autoimmune response in mice compared with humans
• Addressing the regulatory hurdles involved in using a biologic and a chemical component in ASIT therapies
• Looking at the potential for a changing paradigm in clinical development for precision medicine – focussing more on earlier human clinical studies to determine safety and efficacy rather than developing more sophisticated mouse models
